MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Inobrodib

CAS No. : 2222941-37-7

MCE 站：Inobrodib

产品活性：Inobrodib (CCS1477) 是一种口服活性的、有效且选择性强的 p300/CBP 抑制剂。Inobrodib 与 p300 和 CBP 结合，K_d 值为 1.3 和 1.7 nM，与 K_d 为 222 nM 的 BRD4 相比，具有 170/130 倍的选择性。Inobrodib 抑制前列腺癌细胞系的细胞增殖并降低雄激素受体 (AR) 和 C-MYC 调节的基因表达。

研究领域：Epigenetics

作用靶点：Epigenetic Reader Domain

In Vitro: Inobrodib binding to cellular histones in an in-cell BRET assay gives an IC50 of 19 nM for p300 and 1,060 nM for BRD4. Inobrodib shows potent growth-inhibitory activity in VCaP, 22Rv1, and LNCaP95 (all IC50 < 100 nM) that express both AR-FL and AR-V7.
Inobrodib (0-3000 nM; 48 hours) reduces expression of AR-regulated genes (KLK2, KLK3, and TMPRSS2) in both 22Rv1 and LNCaP95 cells. Inobrodib also reduces C-MYC protein expression in both 22Rv1 and LNCaP95 cells and AR-V7 protein expression in 22Rv1 cells, without clear impact on AR-FL protein expression in 22Rv1 and LNCaP95 cells. Inobrodib reduces C-MYC mRNA and downstream AR and C-MYC signaling in 22Rv1 and C4-2 cells at 16 hours. Inobrodib regulates AR signaling by affecting the recruitment of CBP, p300, and AR-FL to known AR binding sites, and has the potential to abrogate persistent AR signaling in CRPC.

In Vivo: Inobrodib (10-30 mg/kg; oral gavage; 10 or 20 mg/kg daily (QD) or 30 mg/kg every other day (QOD) for 28 days) suppresses growth of a 22Rv1 mouse xenograft model with associated reduction in AR signaling.
Inobrodib (20 mg/kg; oral gavage; daily for 8 days) decreases AR and AR-V7 signaling and inhibits growth in a patient- derived model of lethal prostate cancer (NOD/SCID gamma (NSG) male castrated mice).

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Epigenetics Compound Library  |  Histone Modification Research Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Reprogramming Compound Library  |  Anti-Blood Cancer Compound Library  |  (+)-JQ-1  |  A-485  |  Curcumin  |  Birabresib  |  C646  |  BRM/BRG1 ATP Inhibitor-1  |  MZ 1  |  666-15  |  ARV-825  |  ABBV-744  |  dBET6  |  BI 2536  |  ARV-771  |  dBET1  |  I-BET151  |  Anacardic Acid  |  SNDX-5613  |  Molibresib  |  VTP50469  |  SGC-CBP30  |  Mivebresib  |  AZD5153 6-Hydroxy-2-naphthoic acid  |  KG-501  |  MG 149  |  GNE-781  |  MI-3454  |  MI-503  |  Apabetalone  |  A-366

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。